Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3

Human Molecular Genetics

Volumn 22, Issue 13, 2013, Pages 2662-2675

  Chan, Ping K ^a   Torres, Raul ^a   Yandim, Cihangir ^a   Law, Pui P ^a   Khadayate, Sanjay ^b   Mauri, Marta ^a   Grosan, Crina ^c   Chapman Rothe, Nadine ^a   Giunti, Paola ^d   Pook, Mark ^c   Festenstein, Richard ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

^c BRUNEL UNIVERSITY   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYRIBONUCLEASE I; FRATAXIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; NICOTINAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; CHROMATIN STRUCTURE; CHROMOSOME; CONFORMATION; CONTROLLED STUDY; DNA FLANKING REGION; FRIEDREICH ATAXIA; GENE EXPRESSION; GENE LOCUS; HETEROCHROMATIN; HIGH THROUGHPUT SEQUENCING; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; HUMAN TISSUE; LYMPHOBLASTOID CELL LINE; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION INITIATION;

ACETYLATION; ANIMALS; CELL LINE, TRANSFORMED; CHROMATIN; DEOXYRIBONUCLEASE I; EPISTASIS, GENETIC; FRIEDREICH ATAXIA; GENE EXPRESSION REGULATION; GENE ORDER; GENETIC LOCI; HETEROCHROMATIN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; IRON-BINDING PROTEINS; METHYLATION; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; NIACINAMIDE; TRINUCLEOTIDE REPEAT EXPANSION;

MUS MUSCULUS;

EID: 84878912414     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt115     Document Type: Article

References (59)

1. Campuzano, V., Montermini, L., Molto, M.D., Pianese, L., Cossee, M., Cavalcanti, F., Monros, E., Rodius, F., Duclos, F., Monticelli, A. et al. (1996) Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science, 271, 1423-1427.
2. Yoon, T. and Cowan, J.A. (2004) Frataxin-mediated iron delivery to ferrochelatase in the final step of heme biosynthesis. J. Biol. Chem., 279, 25943-25946.
3. Koeppen, A.H., Michael, S.C., Knutson, M.D., Haile, D.J., Qian, J., Levi, S., Santambrogio, P., Garrick, M.D. and Lamarche, J.B. (2007) The dentate nucleus in Friedreich's ataxia: the role of iron-responsive proteins. Acta Neuropathol, 114, 163-173.
4. Punga, T. and Buhler, M. (2010) Long intronic GAA repeats causing Friedreich ataxia impede transcription elongation. EMBO Mol. Med., 2, 120-129.
5. Schulz, J.B., Boesch, S., Burk, K., Durr, A., Giunti, P., Mariotti, C., Pousset, F., Schols, L., Vankan, P. and Pandolfo, M. (2009) Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat. Rev. Neurol., 5, 222-234.
6. Koeppen, A.H. (2011) Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J. Neurol. Sci., 303, 1-12.
7. Ohshima, K., Montermini, L., Wells, R.D. and Pandolfo, M. (1998) Inhibitory effects of expanded GAA.TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J. Biol. Chem., 273, 14588-14595.
8. Bidichandani, S.I., Ashizawa, T. and Patel, P.I. (1998) The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am. J. Hum. Genet., 62, 111-121.
9. Grabczyk, E., Mancuso, M. and Sammarco, M.C. (2007) A persistent RNA.DNA hybrid formed by transcription of the Friedreich ataxia triplet repeat in live bacteria, and by T7 RNAP in vitro. Nucleic Acids Res., 35, 5351-5359.
10. Saveliev, A., Everett, C., Sharpe, T., Webster, Z. and Festenstein, R. (2003) DNA triplet repeats mediate heterochromatin-protein-1-sensitive variegated gene silencing. Nature, 422, 909-913.
11. Festenstein, R. (2006) Breaking the silence in Friedreich's ataxia. Nat. Chem. Biol., 2, 512-513.
12. Herman, D., Jenssen, K., Burnett, R., Soragni, E., Perlman, S.L. and Gottesfeld, J.M. (2006) Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat. Chem. Biol., 2, 551-558.
13. Greene, E., Mahishi, L., Entezam, A., Kumari, D. and Usdin, K. (2007) Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Res., 35, 3383-3390.
14. Al-Mahdawi, S., Pinto, R.M., Ismail, O., Varshney, D., Lymperi, S., Sandi, C., Trabzuni, D. and Pook, M. (2008) The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum. Mol. Genet., 17, 735-746.
15. Dillon, N. and Festenstein, R. (2002) Unravelling heterochromatin: competition between positive and negative factors regulates accessibility. Trends Genet., 18, 252-258.
16. Chou, C.J., Herman, D. and Gottesfeld, J.M. (2008) Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J. Biol. Chem., 283, 35402-35409.
17. Rai, M., Soragni, E., Jenssen, K., Burnett, R., Herman, D., Coppola, G., Geschwind, D.H., Gottesfeld, J.M. and Pandolfo, M. (2008) HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One, 3, e1958.
18. Rai, M., Soragni, E., Chou, C.J., Barnes, G., Jones, S., Rusche, J.R., Gottesfeld, J.M. and Pandolfo, M. (2010) Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS One, 5, e8825.
19. Sandi, C., Pinto, R.M., Al-Mahdawi, S., Ezzatizadeh, V., Barnes, G., Jones, S., Rusche, J.R., Gottesfeld, J.M. and Pook, M.A. (2011) Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol. Dis., 42, 496-505.
20. Gui, C.Y., Ngo, L., Xu, W.S., Richon, V.M. and Marks, P.A. (2004) Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl Acad. Sci. U S A, 101, 1241-1246.
21. Bolden, J.E., Peart, M.J. and Johnstone, R.W. (2006) Anticancer activities of histone deacetylase inhibitors. Nature reviews Drug discovery, 5, 769-784.
22. Gottlicher, M., Minucci, S., Zhu, P., Kramer, O.H., Schimpf, A., Giavara, S., Sleeman, J.P., Lo Coco, F., Nervi, C., Pelicci, P.G. et al. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. The EMBO J, 20, 6969-6978.
23. Beal, M.F., Henshaw, D.R., Jenkins, B.G., Rosen, B.R. and Schulz, J.B. (1994) Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Annals of neurology, 36, 882-888.
24. Bitterman, K.J., Anderson, R.M., Cohen, H.Y., Latorre-Esteves, M. and Sinclair, D.A. (2002) Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem, 277, 45099-45107.
25. Dittenhafer-Reed, K.E., Feldman, J.L. and Denu, J.M. (2011) Catalysis and mechanistic insights into sirtuin activation. Chembiochem: a European journal of chemical biology, 12, 281-289.
26. Vaquero, A., Scher, M., Lee, D., Erdjument-Bromage, H., Tempst, P. and Reinberg, D. (2004) Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell, 16, 93-105.
27. Vaquero, A., Scher, M., Erdjument-Bromage, H., Tempst, P., Serrano, L. and Reinberg, D. (2007) SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation. Nature, 450, 440-444.
28. Hagege, H., Klous, P., Braem, C., Splinter, E., Dekker, J., Cathala, G., de Laat, W. and Forne, T. (2007) Quantitative analysis of chromosome conformation capture assays (3C-qPCR). Nat Protoc, 2, 1722-1733.
29. Simonis, M., Klous, P., Homminga, I., Galjaard, R.J., Rijkers, E.J., Grosveld, F., Meijerink, J.P. and de Laat, W. (2009) High-resolution identification of balanced and complex chromosomal rearrangements by 4C technology. Nat Methods, 6, 837-842.
30. McArthur, M., Gerum, S. and Stamatoyannopoulos, G. (2001) Quantification of DNaseI-sensitivity by real-time PCR: quantitative analysis of DNaseI-hypersensitivity of the mouse beta-globin LCR. J Mol Biol, 313, 27-34.
31. Nelson, J.D., Denisenko, O. and Bomsztyk, K. (2006) Protocol for the fast chromatin immunoprecipitation (ChIP) method. Nat Protoc, 1, 179-185.
32. Coppola, G., Burnett, R., Perlman, S., Versano, R., Gao, F., Plasterer, H., Rai, M., Sacca, F., Filla, A., Lynch, D.R. et al. (2011) A gene expression phenotype in lymphocytes from Friedreich ataxia patients. Annals of neurology, 70, 790-804.
33. Knip, M., Douek, I.F., Moore, W.P., Gillmor, H.A., McLean, A.E., Bingley, P.J. and Gale, E.A. (2000) Safety of high-dose nicotinamide: a review. Diabetologia, 43, 1337-1345.
34. Kumari, D., Biacsi, R.E. and Usdin, K. (2011) Repeat expansion affects both transcription initiation and elongation in friedreich ataxia cells. J Biol Chem, 286, 4209-4215.
35. Kim, E., Napierala, M. and Dent, S.Y. (2011) Hyperexpansion of GAA repeats affects post-initiation steps of FXN transcription in Friedreich's ataxia. Nucleic Acids Res., 39, 8366-8377.
36. De Biase, I., Chutake, Y.K., Rindler, P.M. and Bidichandani, S.I. (2009) Epigenetic silencing in Friedreich ataxia is associated with depletion of CTCF (CCCTC-binding factor) and antisense transcription. PLoS One, 4, e7914.
37. Barski, A., Cuddapah, S., Cui, K., Roh, T.Y., Schones, D.E., Wang, Z., Wei, G., Chepelev, I. and Zhao, K. (2007) High-resolution profiling of histone methylations in the human genome. Cell, 129, 823-837.
38. Rosenbloom, K.R., Sloan, C.A., Malladi, V.S., Dreszer, T.R., Learned, K., Kirkup, V.M., Wong, M.C., Maddren, M., Fang, R., Heitner, S.G. et al. (2012) ENCODE Data in the UCSC Genome Browser: year 5 update. Nucleic Acids Res., 41, D56-D63.
39. Al-Mahdawi, S., Pinto, R.M., Ruddle, P., Carroll, C., Webster, Z. and Pook, M. (2004) GAA repeat instability in Friedreich ataxia YAC transgenic mice. Genomics, 84, 301-310.
40. Young, M.D., Wakefield, M.J., Smyth, G.K. and Oshlack, A. (2010) Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol., 11, R14.
41. Papaccio, G., Ammendola, E. and Pisanti, F.A. (1999) Nicotinamide decreases MHC class II but not MHC class I expression and increases intercellular adhesion molecule-1 structures in non-obese diabetic mouse pancreas. J. Endocrinol., 160, 389-400.
42. Kaneko, S., Wang, J., Kaneko, M., Yiu, G., Hurrell, J.M., Chitnis, T., Khoury, S.J. and He, Z. (2006) Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. J. Neurosci., 26, 9794-9804.
43. Gale, E.A., Bingley, P.J., Emmett, C.L. and Collier, T. (2004) European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet, 363, 925-931.
44. Hiromatsu, Y., Yang, D., Miyake, I., Koga, M., Kameo, J., Sato, M., Inoue, Y. and Nonaka, K. (1998) Nicotinamide decreases cytokine-induced activation of orbital fibroblasts from patients with thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab, 83, 121-124.
45. de Wit, E. and de Laat, W. (2012) A decade of 3C technologies: insights into nuclear organization. Genes Dev., 26, 11-24.
46. Elgin, S.C. (1996) Heterochromatin and gene regulation in Drosophila. Curr. Opin. Genet. Dev., 6, 193-202.
47. Sun, F.L., Cuaycong, M.H. and Elgin, S.C. (2001) Long-range nucleosome ordering is associated with gene silencing in Drosophila melanogaster pericentric heterochromatin. Mol. Cell. Biol., 21, 2867- 2879.
48. Csink, A.K. and Henikoff, S. (1996) Genetic modification of heterochromatic association and nuclear organization in Drosophila. Nature, 381, 529-531.
49. Canzio, D., Chang, E.Y., Shankar, S., Kuchenbecker, K.M., Simon, M.D. et al. (2011) Chromodomain-mediated oligomerization of HP1 suggests a nucleosome-bridging mechanism for heterochromatin assembly. Mol. Cell, 41, 67-81.
50. Grewal, S.I. and Elgin, S.C. (2002) Heterochromatin: new possibilities for the inheritance of structure. Curr. Opin. Genet. Dev., 12, 178-187.
51. Pianese, L., Turano, M., Lo Casale, M.S., De Biase, I., Giacchetti, M., Monticelli, A., Criscuolo, C., Filla, A. and Cocozza, S. (2004) Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriers. J. Neurol. Neurosurg. Psychiatry, 75, 1061-1063.
52. Al-Mahdawi, S., Pinto, R.M., Varshney, D., Lawrence, L., Lowrie, M.B., Hughes, S., Webster, Z., Blake, J., Cooper, J.M., King, R. et al. (2006) GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics, 88, 580-590.
53. Tolhuis, B., Palstra, R.J., Splinter, E., Grosveld, F. and de Laat, W. (2002) Looping and interaction between hypersensitive sites in the active beta-globin locus. Mol. Cell. 10, 1453-1465.
54. Simonis, M., Klous, P., Splinter, E., Moshkin, Y., Willemsen, R., de Wit, E., van Steensel, B. and de Laat, W. (2006) Nuclear organization of active and inactive chromatin domains uncovered by chromosome conformation capture-on-chip (4C). Nat. Genet., 38, 1348-1354.
55. Thongjuea, S., Bergen Center for Computational Science and Norway (2011). r3Cseq: Analysis of Chromosome Conformation Capture and Next-generation Sequencing (3C-seq). R package version 1.4.0.
56. Teixe, T., Nieto-Blanco, P., Vilella, R., Engel, P., Reina, M. and Espel, E. (2008) Syndecan-2 and -4 expressed on activated primary human CD4+ lymphocytes can regulate T cell activation. Mol. Immunol., 45, 2905-919.
57. Trapnell, C., Pachter, L. and Salzberg, S.L. (2009) TopHat: discovering splice junctions with RNA-Seq. Bioinformatics, 25, 1105-1111.
58. Anders, S. and Huber, W. (2010) Differential expression analysis for sequence count data. Genome Biol., 11, R106.
59. Edgar, R., Domrachev, M. and Lash, A.E. (2002) Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res., 30, 207-210.